Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1002892 | 1.00 | MAOA (0.36) | MAOAMAOBADORA2AAPPALDH1A1 | |
| SCHEMBL1002893 | 1.00 | MAOA (0.36) | MAOAMAOBADORA2AAPPALDH1A1 | |
| SCHEMBL1002191 | 0.90 | PPARG (0.39) | ALDH1A1CYP1A2CYP2C19KDM4E | |
| SCHEMBL1002188 | 0.90 | PPARG (0.39) | ALDH1A1CYP1A2CYP2C19KDM4E | |
| SCHEMBL1002189 | 0.90 | PPARG (0.39) | ALDH1A1CYP1A2CYP2C19KDM4E | |
| SCHEMBL1003230 | 0.84 | MCHR1 (0.51) | — | |
| SCHEMBL1003232 | 0.84 | MCHR1 (0.51) | — | |
| SCHEMBL1000688 | 0.74 | KCNH2 (0.41) | CYP1A2CYP2C9CYP2C19KDM4ECYP3A4 | |
| SCHEMBL1000690 | 0.74 | KCNH2 (0.41) | CYP1A2CYP2C9CYP2C19KDM4ECYP3A4 | |
| SCHEMBL1000689 | 0.74 | KCNH2 (0.41) | CYP1A2CYP2C9CYP2C19KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875633-B2 | 4-[(4-Chlorobenzyl)oxy]-1-(4-[(1E)-3-(methylamino)-1-propen-1-yl]phenyl)pyridin-2(1H)-one; remedy for metabolic disorders such as obesity, diabetes, hormone disorder; cardiovascular disorders (stenocardia, acute or congestive heart failure); nervous system disorders (bulimia, anxiety, epilepsy etc.) | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| EP-1921065-B1 | PHENYLPYRIDONE DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20090137587-A1 | Phenylpyridone Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1921065-A1 | PHENYLPYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137587-A1 | Phenylpyridone Derivative | NAT1, NPR1, PC | MAOA 406/4885MAOB 240/4885ADORA2A 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.